Janssen Search
Search results
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Lazertinib, in combination with RYBREVANT®▼ (amivantamab), for the First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer
Dec 21, 2023 Belgium The submission is supported by data from the Phase 3 MARIPOSA study, which featured in a Late-Breaking Presidential Symposium session at the 2023 ESMO Congress [1] Lazertinib is a highly selective, central nervous system-penetrant, ...
Committed to Advancing Prostate Cancer Innovation for Patients
Committed to Advancing Prostate Cancer Innovation for Patients As this year’s American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) is upon us, I’ve been reflecting on the tremendous progress that has been made in the ...
Cancer Interception and the Tumor Microenvironment
Cancer Interception and the Tumor Microenvironment “We are intent on understanding what turns healthy cells into cancerous cells and continue to make progress in this area. These critical insights will help us advance medicines to interrupt the process ...
Harnessing Data to Shape the Future of Regulatory Affairs
Harnessing Data to Shape the Future of Regulatory Affairs As the complexity of our global healthcare environment increases, the significance of integrating novel strategies to address today’s regulatory challenges is a top priority. With Janssen Research ...
PH Partnering
Partner with Janssen in Pulmonary Hypertension Janssen is spearheading a new era for pulmonary hypertension (PH), working to transform the disease into a long-term manageable condition, so that patients can live a normal life. We are focusing our ...
Will Ebola Continue to Re-Emerge?
Will Ebola Continue to Re-Emerge? In this post, Janssen’s Dr. Allitia Di Bernardo looks at how Janssen is fighting to prevent Ebola outbreaks before they begin. Since stepping into my role as Europe, Middle East & Asia (EMEA) Therapeutic Area Lead ...
Janssen Submits Type II Extension of Indication Application to the European Medicines Agency Seeking Approval of RYBREVANT®▼ (amivantamab), in combination with Lazertinib, for First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer
Feb 08, 2024 Belgium The submission is supported by data from the Phase 3 MARIPOSA study, showing statistically significant and clinically meaningful improvement in progression-free survival in patients with EGFR-mutated advanced NSCLC treated with ...
Investigational targeted oral peptide JNJ-2113 demonstrated positive results in moderate-to-severe plaque psoriasis in Phase 2b study published in New England Journal of Medicine
Feb 07, 2024 United States Data from FRONTIER 1, a Phase 2b clinical trial, show JNJ-2113, the first and only targeted oral peptide that selectively blocks the IL-23 receptor, achieved the primary and all secondary endpoints including PASI a 100 and IGA b ...
Facing the alarming truth about AMR
Facing the alarming truth about AMR 3D- render of a germ bacteria under a microscope My journey as a scientist was born out of a lifelong fascination with bacteria, their biology, and their biochemistry as the smallest and earliest forms of life on earth. ...
Jochen Fleischmann
JOCHEN FLEISCHMANN VICE PRESIDENT GLOBAL THERAPEUTIC AREA MARKET ACCESS LEADER IMMUNOLOGY Jochen Fleischmann is the Vice President, Global Therapeutic Area Market Access Leader, Immunology, for the Janssen Pharmaceutical Companies of Johnson & Johnson ...